Table 1.
Summary of cell membrane-camouflaged nanomedicines for cancer therapy.
| Cell Source | Synthetic Carrier | Therapeutic Agent | Fabrication Methods | Cancer Model | Unique Advantages | Refs. |
|---|---|---|---|---|---|---|
| RBC | Fe3O4 MNs | - | Extrusion | CTCs | Reduced non-specific protein adsorption; Prolonged circulation time |
[74] |
| BSA PAAV-SNO |
10-HCPT; ICG IR1061 1-MT |
Sonication and extrusion | HeLa 4T1 |
Synergistic chemo-PTT; Immune evasion ability |
[75,76,77] | |
| Macrophage | Polymer | PTX | Sonication and extrusion | MDA-MB-231 | Tumor-homing ability; Controlled release | [78] |
| TAAM | UCNP | RB | Extrusion | 4T1 | TME targeting | [23] |
| Neutrophils | PLGA | PTX | Sonication and extrusion | SKOV3 | Prolonged circulation time; Enhanced accumulation |
[79] |
| Platelet | Fe3O4 | SAS | Extrusion | 4T1 | Effective ferroptosis; Mild immunogenicity |
[80] |
| NK cell | PLGA | TCPP | Sonication and extrusion | 4T1 | M1-Mφ polarization; Activated effector T cells | [81] |
| T cell | HA-SS-VES | Curcumin | Extrusion | B16 | Bind to PD-L1; Membrane escape effect |
[67] |
| Tumor cell | ||||||
| CT26 | Bi NPs | - | Extrusion | CT26 | Long-term circulation | [82] |
| B16 | USIO NPs | DOX | Extrusion | B16 | Homotypic targeting; Immune escape |
[13] |
| bEnd.3 | (PTX)NS | PTX | Extrusion | bEnd.3 | BBB penetration | [30] |
| Hybrid membrane | ||||||
| RAW264.7 4T1 | PLGA | Met; siFGL1; DOX | Sonication | 4T1 | Lysosomal escape; Targeting metastasis |
[68,72] |
| B16F10; 4T1; M1-Mφ; platelets |
- | - | Sonication and extrusion | B16F10; 4T1 |
Increased affinity to CD47; M2-to-M1 repolarization |
[83] |
| RBC; MCF-7 | Melanin NPs | - | Sonication and extrusion | MCF-7 | Prolonged circulation time;Homotypic targeting | [84] |
Abbreviations: RBC, red blood cell; MNs, magnetic nanoparticles; CTCs, circulating tumor cells; BSA, bovine serum albumin; PAAV-SNO, S-nitrosothiols (SNO)-pendant copolymer (poly(acrylamide-co-acrylonitrile-co-vinylimidazole)-SNO copolymer; PTT, photothermal therapy; RES, reticular endothelial system; TAMM, tumor-associated macrophage membrane; UCNP, upconversion nanoparticle; TME, tumor microenvironment; RB, Rose Bengal; PLGA, poly (lactic-co-glycolic acid); SAS, sulfasalazine; PTX, paclitaxel; NK, natural killer; TCPP, 4,4′,4″,4‴-(porphine-5,10,15,20-tetrayl) tetrakis (benzoic acid); Mφ, macrophage; HA-SS-VES, hyaluronic acid-grated-disulfide bond-vitamin E succinate; PD-L1, programmed cell death ligand-1; CT26, mouse colon cancer CT26 cells; Bi, bismuth; NPs, nanoparticles; B16, mouse melanoma cell line; USIO, ultrasmall iron oxide; DOX, doxorubicin; NS, nanosuspensions; BBB, blood brain barrier; Met, metformin; siFGL1, small interfering fibrinogen-like protein 1.